Dalcetrapib, a cholesteryl ester transfer protein modulator

Bibliography

• Gordon DJ, Probstfield JL, Garrison RJ, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989;79:8-15
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Klerkx AH, Stroes ES, A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Clerc RG, Stauffer A, Weibel F, Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels. J Hypertens 2010;28:1676-86
   PubMed Web of Science ®Google Scholar
• Hooper AJ, Burnett JR. Anacetrapib, a cholesteryl ester transfer protein inhibitor. Expert Opin Investig Drugs 2012;21:103-9
   PubMed Web of Science ®Google Scholar
• Kobayashi J, Okamoto H, Otabe M, Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage. Atherosclerosis 2002;162:131-5
   PubMed Web of Science ®Google Scholar
• Okamoto H, Iwamoto Y, Maki M, Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol 2003;466:147-54
   PubMed Web of Science ®Google Scholar
• Shimoji E, Zhang B, Fan P, Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits. Atherosclerosis 2004;172:247-57
   PubMed Web of Science ®Google Scholar
• Roche. Roche provides update on Phase III study of dalcetrapib. 2012. Available from: http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm [Last accessed 15 May 2012]
   Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
   PubMed Web of Science ®Google Scholar
• Ranalletta M, Bierilo KK, Chen Y, Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010;51:2739-52
   PubMed Web of Science ®Google Scholar
• Okamoto H, Yonemori F, Wakitani K, A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7
   PubMed Web of Science ®Google Scholar
• Derks M, Anzures-Cabrera J, Turnbull L, Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study. Clin Drug Investig 2011;31:325-35
   PubMed Web of Science ®Google Scholar
• Okamoto H, Miyai A, Sasase T, Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma. Clin Chim Acta 2007;375:92-8
   PubMed Web of Science ®Google Scholar
• Niesor EJ, Magg C, Ogawa N, Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010;51:3443-54
   PubMed Web of Science ®Google Scholar
• Derks M, Kawamura H, Abt M, Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers. Clin Ther 2011;33:754-65
   PubMed Web of Science ®Google Scholar
• Derks M, Fowler S, Kuhlmann O. A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 2009;31:586-99
   PubMed Web of Science ®Google Scholar
• Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009;25:891-902
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Parr G, No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin. Expert Opin Investig Drugs 2010;19:1135-45
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Phelan M. Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe. Br J Clin Pharmacol 2010;70:825-33
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Phelan M, Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Pharmacol 2010;50:1188-201
   PubMed Web of Science ®Google Scholar
• de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-65
   PubMed Web of Science ®Google Scholar
• Kuivenhoven JA, de Grooth GJ, Kawamura H, Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005;95:1085-8
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Davidson MH, Robinson JG, Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab 2012;14:30-9
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Mani V, Woodward M, Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59
   PubMed Web of Science ®Google Scholar
• Luscher TF, Taddei S, Kaski JC, Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33:857-65
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ballantyne CM, Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009;158:896-901; e3
   PubMed Web of Science ®Google Scholar
• Stroes ES, Kastelein JJ, Benardeau A, Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats. Br J Pharmacol 2009;158:1763-70
   PubMed Web of Science ®Google Scholar
• Stein EA, Roth EM, Rhyne JM, Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010;31:480-8
   PubMed Web of Science ®Google Scholar
• Stein EA, Stroes ES, Steiner G, Safety and tolerability of dalcetrapib. Am J Cardiol 2009;104:82-91
   PubMed Web of Science ®Google Scholar
• Derks M, Abt M, Mwangi A, Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol 2010;66:775-83
   PubMed Web of Science ®Google Scholar
• Niesor EJ, Chaput E, Staempfli A, Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis 2011;219:761-7
   PubMed Web of Science ®Google Scholar
• Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol 2011;22:288-95
   PubMed Web of Science ®Google Scholar
• Matsuura F, Wang N, Chen W, HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 2006;116:1435-42
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Matsuura F, Wang N, Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 2007;27:1132-8
   PubMed Web of Science ®Google Scholar
• van der Steeg WA, Hovingh GK, Klerkx AH, Cholesteryl ester transfer protein and hyperalphalipoproteinemia in Caucasians. J Lipid Res 2007;48:674-82
   PubMed Web of Science ®Google Scholar
• Nagano M, Yamashita S, Hirano K, Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 2004;11:110-21
   PubMedGoogle Scholar
• Kappelle PJ, van Tol A, Wolffenbuttel BH, Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Cardiovasc Ther 2010;29:e89-99
   PubMed Web of Science ®Google Scholar
• Vasan RS, Pencina MJ, Robins SJ, Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009;120:2414-20
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007;370:153-60
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tardif JC, Nicholls SJ, Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:1304-16
   PubMed Web of Science ®Google Scholar